27th January 2022

Musgrove patients first to take part in global study for Crohn’s disease

Musgrove Park Hospital has successfully recruited the first two patients to a global study for Crohn’s disease.

The study, STARDUST, looks at different dosing strategies for a National Institute for Health and Care Excellence (NICE) approved drug used in people with the debilitating inflammatory bowel disease.

It is the first commercial study the gastroenterology team at Musgrove Park has recruited to.

Emma Wesley, consultant gastroenterologist at Musgrove, heads up research in the department.

She said:

“It’s amazing to have not only enrolled the first patient globally into this study, but also the second patient. It really has created quite a stir.

We’ve only recently started doing commercial studies. This particular study opened in April 2017 and we have already hit our target and now have other commercial studies open for recruitment.

I wanted to do more research in the department because I felt it would be a good thing to be able to offer our patients but also, as clinicians, being involved in research helps to keep us up to date.

In the future we hope to be able to offer drugs to our patients that wouldn’t otherwise be available to them other than via a clinical trial, particularly for those people for whom there aren’t any other options.”

Emma said the recent successes of the department are not solely down to her, but the whole team.

“I’m really lucky that I work with a fantastic team” said Emma.

“We all work well together which has been the key to our success.”